https://www.nice.org.uk/guidance/ta538/informationforpublic
Information for the public | Dinutuximab beta for treating neuroblastoma | Guidance | NICE
Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over
information for the publicdinutuximab betatreatingneuroblastomaguidance
https://www.nice.org.uk/guidance/ta538/chapter/1-Recommendations
1 Recommendations | Dinutuximab beta for treating neuroblastoma | Guidance | NICE
Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over
dinutuximab beta1recommendationstreatingneuroblastoma
https://www.nice.org.uk/guidance/ta538/evidence
Evidence | Dinutuximab beta for treating neuroblastoma | Guidance | NICE
Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over
dinutuximab betaevidencetreatingneuroblastomaguidance
https://www.nice.org.uk/guidance/ta538/chapter/4-Implementation
4 Implementation | Dinutuximab beta for treating neuroblastoma | Guidance | NICE
Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over
dinutuximab beta4implementationtreatingneuroblastoma
https://www.news-medical.net/news/20251212/Dinutuximab-beta-plus-chemotherapy-shrinks-neuroblastoma-tumors-in-children.aspx
Dinutuximab beta plus chemotherapy shrinks neuroblastoma tumors in children
Dec 14, 2025 - Children with a rare form of cancer called neuroblastoma which hasn't responded to initial treatment or that has relapsed may benefit from adding antibody...
dinutuximab betapluschemotherapyshrinksneuroblastoma
https://www.nice.org.uk/guidance/ta538/chapter/5-Appraisal-committee-members-and-NICE-project-team
5 Appraisal committee members and NICE project team | Dinutuximab beta for treating neuroblastoma |...
Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over